1. BIO Announces Life Sciences Companies Selected to Present at the 9th Annual BIO Investor Forum
(News/Breaking News)

... Ltd. ASX:LCTMirna Therapeutics, Inc.Nuon Therapeutics, Inc.Oncolytics Biotech Inc. ONCYPalatin Technologies AMEX: PTNPLx Pharma, Inc.Relypsa, Inc.RXi Pharmaceuticals Corp. RXIISangart, Inc.Somaxon ...

2. Cardiome Pharma falls on clinical program delay. Repros awarded key patent
(Home Page/Home Page)

... OXIS, Paris: OXI) announced today the addition of Dr. Stephen Coles as the newest member to its Scientific Advisory Board. RXi Pharmaceuticals Corporation (Nasdaq: RXII), a recognized leader in RNAi-based ...

3. RXi Pharmaceuticals Reports Financial Results for the Second Quarter of 2010
(News/Breaking News)

WORCESTER, Mass.--RXi Pharmaceuticals Corporation (Nasdaq: RXII), a recognized leader in RNAi-based therapeutic discovery and development, today reported its financial results for the second quarter ...

4. RXi Pharmaceuticals Reports Financial Results for the Second Quarter of 2010
(News/Breaking News)

WORCESTER, Mass.--(BUSINESS WIRE)--RXi Pharmaceuticals Corporation (Nasdaq: RXII), a recognized leader in RNAi-based therapeutic discovery and development, today reported its financial results fothe ...

5. CytRx Reports 2010 Second Quarter Financial Results
(News/Breaking News)

... of RXi Pharmaceuticals (Nasdaq:RXII), bringing total comprehensive income for the second quarter of 2010 to $9.3 million, This compares with a net loss for the three months ended June 30, 2009 of $2.2 ...

6. Affymax soars on drug candidate update. After the bell: Depomed in deal with J&J unit
(Home Page/Home Page)

... August 13, 2010. RXi Pharmaceuticals Corporation (Nasdaq: RXII), a recognized leader in RNAi-based therapeutic discovery and development, today announced that it will release fi ancial results for the ...

7. Bapineuzumab and Intellect Neurosciences Attracting Attention
(Home Page/Home Page)

... subsidiary, RXi Pharmaceuticals Corporation (NasdaqCM: RXII). That move gave CYTR the opportunity to raise money for their RNA interference division and the share structure of the new company was much ...

8. CytRx Announces Substantial Progress with Its Bafetinib Clinical Trials Program
(News/Breaking News)

... maintains a 17% equity interest in publicly traded RXi Pharmaceuticals, Inc. (NASDAQ:RXII). For more information on the Company, visit http://www.cytrx.com. Forward-Looking Statements This press ...

9. Emergent BioSolutions signs BARDA contract. Meridian receives FDA clearence for bacterium test
(Home Page/Home Page)

... (Nasdaq: RXII), a recognized leader in RNAi-based therapeutic discovery and development, today announced that it was awarded an Advanced Technology Small Business Innovation Research (SBIR) grant by the ...

10. RXi Pharmaceuticals Awarded NIH Grant to Advance RNAi Therapeutics
(News/Breaking News)

WORCESTER, Mass.--RXi Pharmaceuticals Corporation (Nasdaq: RXII), a recognized leader in RNAi-based therapeutic discovery and development, today announced that it was awarded an advanced Technology ...

11. CytRx Set to Join the Russell 3000 Index
(News/Breaking News)

... RXi Pharmaceuticals, Inc. (NASDAQ:RXII). For more information on the Company, visit http://www.cytrx.com. Forward-Looking Statements This press release contains forward-looking statements within ...

12. Update to the biotech M&A stories
(Premium Content/Subscriber Only Content)

... we have on both those companies: First, we hear that RXi Pharmaceuticals Corporation (Nasdaq: RXII) has continued meetings and is, indeed, close to finalizing some collaboration and/or partnership agreements ...

13. Cyclacel reports postive Phase II data. MannKind says insulin drug meets trial goal. Human Genome submits lupus drug for FDA approval
(Home Page/Home Page)

... profile for apixaban compared to aspirin. RXi Pharmaceuticals Corporation (Nasdaq: RXII) today announced the company’s new focused RNAi therapeutic strategy at the Jefferies 2010 Global Life Sciences ...

14. More Mergers and Acquisitions Coming to Biotech Sector
(Home Page/Home Page)

... players is RXi Pharmaceuticals Corporation (Nasdaq: RXII). RXi's proprietary sd-rxRNA molecules, which have unique properties of 'self delivery' seem to be the focus of the interest. Earlier in the year, ...

15. RXi Pharmaceuticals Announces New Focused Therapeutic Strategy for its Next Generation RNAi Technology
(News/Breaking News)

WORCESTER, Mass.--(BUSINESS WIRE)--RXi Pharmaceuticals Corporation (Nasdaq: RXII), a recognized leader in RNAi-based therapeutic discovery and development, today announced the company’s new focsed ...

16. RXi Pharmaceuticals Announces New Focused Therapeutic Strategy for its Next Generation RNAi Technology
(News/Breaking News)

WORCESTER, Mass.--RXi Pharmaceuticals Corporation (Nasdaq: RXII), a recognized leader in RNAi-based therapeutic discovery and development, today announced the company's new focused RNAi therapeutic ...

17. CytRx Announces Issuance of Key U.S. Patent Covering Bafetinib
(News/Breaking News)

... proteins associated with disease. CytRx also maintains a 28% equity interest in publicly traded RXi Pharmaceuticals, Inc. (NASDAQ:RXII). For more information on the Company, visit http://www.cytrx.com. ...

18. Javelin sues Hospira. FDA clears Abbott ovarian cancer test. After the bell: SCOLR Pharma tumbles on revenue forecast
(Home Page/Home Page)

... (Nasdaq: RXII) and Royal Philips Electronics (NYSE: PHG, AEX: PHI) today announced that they have entered into a joint research agreement to explore the benefits of combining proprietary technologies from ...

19. Philips and RXi Pharmaceuticals Sign Agreement to Jointly Research Innovative Image-Guided Therapy Concepts Based on RNAi
(News/Breaking News)

EINDHOVEN, Netherlands & WORCESTER, Mass.--(BUSINESS WIRE)--Royal Philips Electronics (NYSE: PHG, AEX: PHI) and RXi Pharmaceuticals Corporation (Nasdaq: RXII), a US-based biopharmaceutical compan, today ...

20. AVI BioPharma reports positive muscle drug data. Arena announces advisory committee review date. BSD Medical shows promise with pancreatic cancer treatment
(Home Page/Home Page)

... (ASCO) Annual Meeting in Chicago, IL from June 4 to June 8, 2010. RXi Pharmaceuticals Corporation (Nasdaq: RXII), a recognized leader in RNAi-based therapeutic discovery and development, today announced ...

21. RXi Pharmaceuticals CEO to Present at the Jefferies 2010 Global Life Sciences Conference
(News/Breaking News)

WORCESTER, Mass.--RXi Pharmaceuticals Corporation (Nasdaq: RXII), a recognized leader in RNAi-based therapeutic discovery and development, today announced that the Company's President and Chief Executive ...

22. RXi Pharmaceuticals CEO to Present at the Jefferies 2010 Global Life Sciences Conference
(News/Breaking News)

WORCESTER, Mass.--(BUSINESS WIRE)--RXi Pharmaceuticals Corporation (Nasdaq: RXII), a recognized leader in RNAi-based therapeutic discovery and development, today announced that the Company's Presdent ...

23. CytRx Initiates Phase 2 Clinical Trial with Bafetinib in B-cell Chronic Lymphocytic Leukemia
(News/Breaking News)

... degrade misfolded proteins associated with disease. CytRx also maintains a 28% equity interest in publicly traded RXi Pharmaceuticals, Inc. (NASDAQ:RXII). For more information on the Company, visit www.cytrx.com. ...

24. Research Trial Evaluating CytRx’s Bafetinib in Brain Tumor Model to be Presented at the American Society of Clinical Oncology (ASCO) Annual Meeting
(News/Breaking News)

... degrade misfolded proteins associated with disease. CytRx also maintains a 28% equity interest in publicly traded RXi Pharmaceuticals, Inc. (NASDAQ:RXII). For more information on the Company, visit www.cytrx.com.  ...

25. Research Trial Evaluating CytRx's Bafetinib in Brain Tumor Model to be Presented at the American Society of Clinical Oncology (ASCO) Annual Meeting
(News/Breaking News)

... degrade misfolded proteins associated with disease. CytRx also maintains a 28% equity interest in publicly traded RXi Pharmaceuticals, Inc. (NASDAQ:RXII). For more information on the Company, visit www.cytrx.com. ...

26. ARCA biopharma reaches SPA with FDA. FDA grants NeoPharm IPF drug Orphan Status. Aeterna Zentaris gains Orphan designation with EU for ovarian cancer drug
(Home Page/Home Page)

... and Chief Executive Officer of the Company. RXi Pharmaceuticals Corporation (Nasdaq: RXII), today reported its financial results for the quarter ended March 31, 2010. "We have continued to make excellent ...

27. RXi Pharmaceuticals Reports Financial Results for the First Quarter of 2010
(News/Breaking News)

WORCESTER, Mass.--RXi Pharmaceuticals Corporation (Nasdaq: RXII), a biopharmaceutical company pursuing the development and commercialization of proprietary therapeutics based on RNA interference (RNAi), ...

28. RXi Pharmaceuticals Reports Financial Results for the First Quarter of 2010
(News/Breaking News)

WORCESTER, Mass.--(BUSINESS WIRE)--RXi Pharmaceuticals Corporation (Nasdaq: RXII), a biopharmaceutical company pursuing the development and commercialization of proprietary therapeutics based onNA interference ...

29. Response Genetics gains on license deal with GSK. MAP jumps on Phase III update. After the bell Achillion Pharma surges on positive data
(Home Page/Home Page)

... 10X Fund, L.P., which is purchasing unregistered Series B convertible preferred stock and warrants. RXi Pharmaceuticals Corporation (Nasdaq: RXII), a biopharmaceutical company pursuing the development ...

30. RXi Pharmaceuticals CEO to Present at the Rodman & Renshaw Annual Global Healthcare Conference
(News/Breaking News)

WORCESTER, Mass.--(BUSINESS WIRE)--RXi Pharmaceuticals Corporation (Nasdaq: RXII), a biopharmaceutical company pursuing the development and commercialization of proprietary therapeutics based onNA interference ...

31. CytRx to Present at the Rodman & Renshaw Annual Global Healthcare Conference in London
(News/Breaking News)

... RXII). For more information on the Company, visit www.cytrx.com.  ...

32. CytRx Reports 2010 First Quarter Financial Results
(News/Breaking News)

... to repair or degrade misfolded proteins associated with disease. CytRx also maintains a 28% equity interest in publicly traded RXi Pharmaceuticals Corporation (NASDAQ: RXII). For more information on ...

33. Akorn soars on strong earnings, ups guidance. Radiant surges on cancer test validation. After the bell InterMune sinks on FDA denial, Myriad drops on weak earnings.
(Home Page/Home Page)

... and warrants. This tranche brings the total raised to date from the 10X Fund to approximately $5.4 million. RXi Pharmaceuticals Corporation (Nasdaq: RXII) today announced new preclinical data obtained ...

34. CytRx's INNO-206 Rapidly Shrinks Human Tumors in an Animal Model of Multiple Myeloma
(News/Breaking News)

... RXi Pharmaceuticals, Inc. (NASDAQ:RXII). For more information on the Company, visit www.cytrx.com. Forward-Looking Statements This press release contains forward-looking statements within the meaning ...

35. MannKind reports AFREZZA is both effective and safe. IDEXX jumps on strong earnings
(Home Page/Home Page)

... recruitment for the Phase II clinical trial on the intravenously administered study drug Elafin. RXi Pharmaceuticals Corporation (Nasdaq: RXII), a biopharmaceutical company pursuing the development and ...

36. Prana Biotechnology soars on Alzheimer's trial data. Cadence re-submits NDA. After the bell, Array BioPharma flys on Novartis agreement
(Home Page/Home Page)

... (Nasdaq: RXII), a biopharmaceutical company pursuing the development and commercialization of proprietary therapeutics based on RNA interference (RNAi), today announced that Anastasia Khvorova, Ph.D., ...

37. RXi Pharmaceuticals Presents at AACR Conference, Highlighting the Potential for RNAi Therapeutics in Oncology
(News/Breaking News)

WORCESTER, Mass.--RXi Pharmaceuticals Corporation (Nasdaq: RXII), a biopharmaceutical company pursuing the development and commercialization of proprietary therapeutics based on RNA interference ...

38. RXi Pharmaceuticals Presents at AACR Conference, Highlighting the Potential for RNAi Therapeutics in Oncology
(News/Breaking News)

WORCESTER, Mass.--(BUSINESS WIRE)--RXi Pharmaceuticals Corporation (Nasdaq: RXII), a biopharmaceutical company pursuing the development and commercialization of proprietary therapeutics based onNA interference ...

39. "Future Leaders in the Biotech Industry" Attracts Standing Room Only Audience
(News/Breaking News)

...  Regulus Therapeutics Inc. Relypsa Inc. RXi Pharmaceuticals Corp. (RXII) Seaside Therapeutics LLC Singulex Inc. SuperGen Inc. (SUPG) Trubion Inc. (TRBN) Vivus Inc. (VVUS) Wilex AG (Xetra: ...

40. Javelin spurns Myriad bid, goes with Hospira. Radient continues higher. Molecular Insight soars after the bell
(Home Page/Home Page)

... for the retinal and glaucoma therapeutic areas. RXi Pharmaceuticals Corporation (Nasdaq: RXII), and miRagen Therapeutics, Inc., a biopharmaceutical company focused on improving patients’ lives by developing ...

41. RXi Pharmaceuticals and miRagen Therapeutics Announce Formation of Research Collaboration in the Field of microRNA
(News/Breaking News)

WORCESTER, Mass. & BOULDER, Colo.--(BUSINESS WIRE)--RXi Pharmaceuticals Corporation (Nasdaq: RXII), a biopharmaceutical company pursuing the development and commercialization of proprietary theraeutics ...

42. RXi Pharmaceuticals and miRagen Therapeutics Announce Formation of Research Collaboration in the Field of microRNA
(News/Breaking News)

WORCESTER, Mass. & BOULDER, Colo.--RXi Pharmaceuticals Corporation (Nasdaq: RXII), a biopharmaceutical company pursuing the development and commercialization of proprietary therapeutics ...

43. BIO Announces Business Forum Company Presentations at the 2010 BIO International Convention
(News/Breaking News)

... Roche (RHHBY) RXI Pharmaceuticals Corp. (RXII) sanofi pasteur Shionogi (TYO: 5407) Spectrum Pharmaceuticals Inc. (SPPI) Synergy Pharmaceuticals, Inc. (SGYP) Takeda (TYO: 4502)  ...

44. Thomson Reuters and BioCentury Convene Future Leaders in the Biotech Industry
(News/Breaking News)

... Therapeutics Inc. Regulus Therapeutics Inc. Relypsa Inc. RXi Pharmaceuticals Corp. (RXII) Seaside Therapeutics LLC Singulex Inc. SuperGen Inc. (SUPG) Trubion Inc. (TRBN) Vivus Inc. (VVUS) ...

45. CytRx to Initiate a Phase 2 Clinical Trial with Bafetinib in Advanced Prostate Cancer
(News/Breaking News)

... or degrade misfolded proteins associated with disease. CytRx also maintains a 28% equity interest in publicly traded RXi Pharmaceuticals, Inc. (NASDAQ:RXII). For more information on the Company, visit ...

46. Genta soars after FDA fast track designation. Opexa Therapeutics moves higher ahead of Multiple Sclerosis therapy data
(Home Page/Home Page)

... at $2.03. RXi Pharmaceuticals Corporation (Nasdaq: RXII), a biopharmaceutical company pursuing the development and commercialization of proprietary therapeutics based on RNA interference (RNAi), and ...

47. RXi Pharmaceuticals and TransDerm Announce Formation of Research Collaboration
(News/Breaking News)

WORCESTER, Mass. & SANTA CRUZ, Calif.--(BUSINESS WIRE)--RXi Pharmaceuticals Corporation (Nasdaq: RXII), a biopharmaceutical company pursuing the development and commercialization of proprietary terapeutics ...

48. RXi Pharmaceuticals and TransDerm Announce Formation of Research Collaboration
(News/Breaking News)

WORCESTER, Mass. & SANTA CRUZ, Calif.--RXi Pharmaceuticals Corporation (Nasdaq: RXII), a biopharmaceutical company pursuing the development and commercialization of proprietary therapeutics based ...

49. RxNews Recap for Thursday 04-01-10. Investors applaud MDRNA's aquisition of Cequent. Amag in licensing deal with Takeda. After the bell RegeneRx receives going concern notification.
(Home Page/Home Page)

... Corporation (Nasdaq: RXII), a biopharmaceutical company pursuing the development and commercialization of proprietary therapeutics based on RNA interference (RNAi), today announced that the Company's President ...

50. RXi Pharmaceuticals CEO to Present at the Future Leaders in the Biotech Industry Investment Conference
(News/Breaking News)

WORCESTER, Mass.--(BUSINESS WIRE)--RXi Pharmaceuticals Corporation (Nasdaq: RXII), a biopharmaceutical company pursuing the development and commercialization of proprietary therapeutics based onNA interference ...